(Q37301312)

19 August 2017

1 reference

title

Relapsed acute lymphoblastic leukemia: current status and future opportunities (English)

1 reference

19 August 2017

1 reference

lymphoblastic leukemia

1 reference

2

Paul Gaynon

1 reference

19 August 2017

Theresa M Harned

1

1 reference

19 August 2017

1 November 2008

1 reference

19 August 2017

Current Oncology Reports

1 reference

19 August 2017

10

1 reference

19 August 2017

453-458

1 reference

19 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-008-0070-3

19 August 2017

0 references

cites work

Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias

1 reference

12 December 2020

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

12 December 2020

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

12 December 2020

The National Cancer Data Base report on patterns of childhood cancers in the United States

1 reference

12 December 2020

A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.

1 reference

12 December 2020

1 reference

12 December 2020

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

1 reference

12 December 2020

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

The long and winding road of the clinical development of Nelarabine

1 reference

12 December 2020

Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia

1 reference

12 December 2020

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

1 reference

12 December 2020

High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience

1 reference

12 December 2020

Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

1 reference

12 December 2020

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

1 reference

12 December 2020

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

12 December 2020

Biochemical modulation of cytarabine triphosphate by clofarabine.

1 reference

12 December 2020

A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia

1 reference

12 December 2020

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

1 reference

12 December 2020

Epratuzumab in the therapy of oncological and immunological diseases

1 reference

12 December 2020

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study

1 reference

12 December 2020

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

1 reference

12 December 2020

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

1 reference

12 December 2020

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

1 reference

12 December 2020

Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

1 reference

12 December 2020

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

1 reference

12 December 2020

Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

1 reference

12 December 2020

Treatment of acute lymphoblastic leukemia

1 reference

12 December 2020

Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.

1 reference

12 December 2020

Childhood acute lymphoblastic leukaemia and relapse

1 reference

12 December 2020

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Mar

1 reference

12 December 2020

Allogeneic transplantation for childhood ALL.

1 reference

12 December 2020

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the C

1 reference

12 December 2020

Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.

1 reference

12 December 2020

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

1 reference

12 December 2020

10.1007/S11912-008-0070-3

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18928659